Collectively, the data presented here confirm a role for galectin-1 as a mediator of pathobiology in myeloid malignancies and worthy of further exploration as a therapeutic target that has the potential to modify the disease course. The gene discussed is LGALS1; the disease is myeloid neoplasm.